Read our COVID-19 research and news.


Experimental drug may slow cognitive decline in early Alzheimer’s

Today, drugmaker Eli Lilly announced preliminary results for a phase II trial showing a monoclonal antibody slowed cognitive decline in patients with early symptoms of Alzheimer’s disease, STAT reports. Volunteers taking donanemab, which targets the beta-amyloid plaques that build up in the brains of Alzheimer’s patients, saw their scores on cognitive tests decline 32% more slowly over the course of 76 weeks than those who received a placebo. What those results mean is still unclear, as the study enrolled just a small group of 272 people, and the researchers have not yet released details on the statistical significance of the data.

Latest News